Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930991 · ClinicalTrials.gov registry record · Early Phase 1
High Dose Omeprazole in Patients With Pancreatic Cancer
A Early Phase 1 study of Exocrine Pancreatic Cancer, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04930991: Recruiting Early Phase 1 study of Exocrine Pancreatic Cancer, sponsored by University of Oklahoma.
NCT04930991 is a Early Phase 1 study of Exocrine Pancreatic Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 60 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04930991, a Early Phase 1 study of Exocrine Pancreatic Cancer, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
Primary Outcome
Proportion of subjects receiving study treatment without adverse events that would significantly delay the surgery
Conditions Studied
Interventions
- DRUG Omeprazole
Study Locations (1)
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
What NCT04930991 shows while recruiting
NCT04930991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Exocrine Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Omeprazole is the first listed.
NCT04930991 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04930991 about?
NCT04930991 is a clinical study titled "High Dose Omeprazole in Patients With Pancreatic Cancer". The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
What is the current status of trial NCT04930991?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2021-09-07. Estimated completion is 2027-09.
What conditions does trial NCT04930991 study?
This clinical trial studies the following conditions: Exocrine Pancreatic Cancer.
What interventions are being tested in trial NCT04930991?
The interventions under investigation include: Omeprazole (DRUG).
Who is sponsoring clinical trial NCT04930991?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04930991 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exocrine Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04930991's enrollment target sits among peer trials
60 403rd of 2000 higher than 1,565 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI